Highlights Kiniksa Pharmaceuticals, Ltd.

Equities

KNSA

BMG5269C1010

Market Closed - Nasdaq Other stock markets 01:30:00 16/05/2024 am IST			5-day change	1st Jan Change
20.1 ^USD	+3.18%		-0.79%	+14.60%

14/05	Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM
23/04	Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises	23/04	MT
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Posts Q1 Revenue $79.9M, vs. Street Est of $78.5M	23/04	MT
Kiniksa Pharmaceuticals, Ltd. Updates Earnings Guidance for 2024	23/04	CI
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	23/04	CI
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart	02/04	CI
Kiniksa Pharmaceuticals' Q4 Earnings, Revenue Increase	28/02	MT
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q4 Revenue $83.4M, vs. Street Est of $72.3M	28/02	MT
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02	CI
Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for the Year 2024	09/01	CI
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q3 Revenue $67M, vs. Street Est of $64.4M	31/23/31	MT
Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for 2023	31/23/31	CI
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	31/23/31	CI
Kiniksa Pharmaceuticals' Shares Rise as Q2 Net Income, Revenue Advance	25/23/25	MT
- (KNSA) KINIKSA PHARMACEUTICALS Q2 EPS $0.21	25/23/25	MT
Kiniksa Pharmaceuticals Q2 Net Income, Revenue Gain	25/23/25	MT
(KNSA) KINIKSA PHARMACEUTICALS Sees Q3 EPS $0.21	25/23/25	MT
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q2 Revenue $71.5M, vs. Street Est of $52.2M	25/23/25	MT
Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for 2023	25/23/25	CI
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/23/25	CI
Kiniksa Pharmaceuticals Jumps After Q1 Results Beat Estimates	02/23/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kiniksa Pharmaceuticals, Ltd.

Equities

KNSA

BMG5269C1010

Highlights

Filters